MDimune has developed a robust IP portfolio to provide freedom to operate. Additional composition of matter claims will be able to be generated to protect collaborative programs.
- Over 50 patents are filed from 10+ patent families
- 18+ patents are registered globally, including those with the US, EU, China, Japan, and Korea
- Patents in 4 main categories - extrusion technology, therapeutic use, targeted delivery, and drug loading